WO2006044509A3 - Methods of treating vascular injuries - Google Patents

Methods of treating vascular injuries Download PDF

Info

Publication number
WO2006044509A3
WO2006044509A3 PCT/US2005/036770 US2005036770W WO2006044509A3 WO 2006044509 A3 WO2006044509 A3 WO 2006044509A3 US 2005036770 W US2005036770 W US 2005036770W WO 2006044509 A3 WO2006044509 A3 WO 2006044509A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypertension
methods
treating vascular
restenosis
vascular injuries
Prior art date
Application number
PCT/US2005/036770
Other languages
French (fr)
Other versions
WO2006044509A2 (en
Inventor
Leona E Ling
Kai Fu
Alan Gill
Philip J Gotwals
Original Assignee
Biogen Idec Inc
Leona E Ling
Kai Fu
Alan Gill
Philip J Gotwals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Leona E Ling, Kai Fu, Alan Gill, Philip J Gotwals filed Critical Biogen Idec Inc
Priority to JP2007536868A priority Critical patent/JP2008516962A/en
Priority to CA002584248A priority patent/CA2584248A1/en
Priority to EP05813747A priority patent/EP1804801A2/en
Priority to AU2005295734A priority patent/AU2005295734A1/en
Publication of WO2006044509A2 publication Critical patent/WO2006044509A2/en
Publication of WO2006044509A3 publication Critical patent/WO2006044509A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention relates to use of compounds and implantable devices including those compounds in treating, preventing, or reducing intimal thickening, vascular remodeling, restenosis (e.g., coronary, peripheral, carotid restenosis), vascular diseases, (e.g., organ transplant-related, cardiac, lung and renal), and hypertension (e.g., primary and secondary hypertension, systolic hypertension, pulmonary hypertension, and hypertension-induced vascular remodeling resulting in target organ damage).
PCT/US2005/036770 2004-10-15 2005-10-13 Methods of treating vascular injuries WO2006044509A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007536868A JP2008516962A (en) 2004-10-15 2005-10-13 How to treat vascular injury
CA002584248A CA2584248A1 (en) 2004-10-15 2005-10-13 Methods of treating vascular injuries
EP05813747A EP1804801A2 (en) 2004-10-15 2005-10-13 Methods of treating vascular injuries
AU2005295734A AU2005295734A1 (en) 2004-10-15 2005-10-13 Methods of treating vascular injuries

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61911604P 2004-10-15 2004-10-15
US60/619,116 2004-10-15

Publications (2)

Publication Number Publication Date
WO2006044509A2 WO2006044509A2 (en) 2006-04-27
WO2006044509A3 true WO2006044509A3 (en) 2006-08-17

Family

ID=36203501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/036770 WO2006044509A2 (en) 2004-10-15 2005-10-13 Methods of treating vascular injuries

Country Status (6)

Country Link
EP (1) EP1804801A2 (en)
JP (1) JP2008516962A (en)
AR (1) AR051587A1 (en)
AU (1) AU2005295734A1 (en)
CA (1) CA2584248A1 (en)
WO (1) WO2006044509A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2008009077A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
PT2049502E (en) 2006-07-28 2012-04-02 Novartis Ag 2,4-substituted quinazolines as lipid kinase inhibitors
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
EP3443958A1 (en) 2006-11-22 2019-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
AR068877A1 (en) * 2007-10-17 2009-12-09 Novartis Ag IMIDAZOL HETEROCICLIC DERIVATIVES
EP2402332A3 (en) * 2008-01-25 2014-10-29 E.I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
CL2009000904A1 (en) * 2008-04-21 2010-04-30 Shionogi & Co Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
JP5640005B2 (en) 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド Imidazosylpyridine compounds as HDAC and / or CDK inhibitors
JP5640006B2 (en) 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド Condensed heterocyclic inhibitors of histone deacetylases and / or cyclin-dependent kinases
BRPI0916713A2 (en) 2008-07-28 2015-11-10 Gilead Science Inc cycloalkylidene and heterocycloalkylidene histone deacetylase inhibiting compounds
WO2010080357A1 (en) * 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
NZ596123A (en) * 2009-05-19 2014-08-29 Dow Agrosciences Llc Compounds and methods for controlling fungi
ES2463826T3 (en) 2009-06-08 2014-05-29 Gilead Sciences, Inc. HDAC inhibitor compounds of cycloalkylcarbamate benzamide aniline
BRPI1010884A2 (en) 2009-06-08 2016-03-15 Gilead Sciences Inc hdac alkanoylamino benzamide aniline inhibitors compound
EP2493889B1 (en) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
BR112012014858A2 (en) * 2009-12-18 2016-03-29 Mitsubishi Tanabe Pharma Corp antiplatelet agent
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
JP5959330B2 (en) * 2011-06-17 2016-08-02 田辺三菱製薬株式会社 New antiplatelet drugs
EA027418B1 (en) 2011-06-27 2017-07-31 Янссен Фармацевтика Нв 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES, PHARMACEUTICAL COMPOSITION BASED THEREON, PROCESSES FOR PREPARING AND USING THE SAME, INTERMEDIATES
CN104507933B (en) * 2012-05-31 2017-10-31 霍夫曼-拉罗奇有限公司 Amido quinazoline and Pyridopyrimidine derivatives
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
ES2592704T3 (en) * 2012-07-26 2016-12-01 F. Hoffmann-La Roche Ag Neurogenesis bencisoxazole modulators
JP6298472B2 (en) 2012-11-19 2018-03-20 ノバルティス アーゲー Compounds and compositions for the treatment of parasitic diseases
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10233170B2 (en) * 2014-04-08 2019-03-19 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
ES2974991T3 (en) 2016-09-19 2024-07-02 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and an ERK inhibitor
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN114105958B (en) * 2021-12-03 2022-11-22 郑州大学第一附属医院 Hydroximic acid-containing 2-phenylamino pyrimidine derivatives and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087304A2 (en) * 2002-04-04 2003-10-23 Biogen, Inc. Tri-substituted heteroaryls and methods of making and using the same
WO2004022054A1 (en) * 2002-09-06 2004-03-18 Biogen Idec Ma Inc. Pyrazolopyridines and methods of making and using the same
WO2004021989A2 (en) * 2002-09-06 2004-03-18 Biogen Idec Ma Inc. Imidazolopyridines and methods of making and using the same
WO2004026306A2 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004060362A2 (en) * 2003-01-02 2004-07-22 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-β
WO2004072033A2 (en) * 2003-02-12 2004-08-26 Biogen Idec Ma Inc. Pyrazoles and methods of making and using the same
WO2004078110A2 (en) * 2003-03-04 2004-09-16 Pfizer Products Inc. Fused imizadoles as transforming growth factor (tgf) inhibitors
WO2006026306A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as tgf-beta inhibitors
WO2006026305A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc Pyrimidinylpyrazoles as tgf-beta inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087304A2 (en) * 2002-04-04 2003-10-23 Biogen, Inc. Tri-substituted heteroaryls and methods of making and using the same
WO2004022054A1 (en) * 2002-09-06 2004-03-18 Biogen Idec Ma Inc. Pyrazolopyridines and methods of making and using the same
WO2004021989A2 (en) * 2002-09-06 2004-03-18 Biogen Idec Ma Inc. Imidazolopyridines and methods of making and using the same
WO2004026306A2 (en) * 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004060362A2 (en) * 2003-01-02 2004-07-22 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-β
WO2004072033A2 (en) * 2003-02-12 2004-08-26 Biogen Idec Ma Inc. Pyrazoles and methods of making and using the same
WO2004078110A2 (en) * 2003-03-04 2004-09-16 Pfizer Products Inc. Fused imizadoles as transforming growth factor (tgf) inhibitors
WO2006026306A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as tgf-beta inhibitors
WO2006026305A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc Pyrimidinylpyrazoles as tgf-beta inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYAN SARAH T ET AL: "Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury.", JOURNAL OF VASCULAR RESEARCH, vol. 40, no. 1, 2003, pages 37 - 46, XP009066791, ISSN: 1018-1172 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994185B2 (en) 2008-05-06 2011-08-09 Glaxo Smith Kline LLC Benzene sulfonamide thiazole and oxazole compounds
US9233956B2 (en) 2008-05-06 2016-01-12 Novartis Ag Benzene sulfonamide thiazole and oxazole compounds
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK

Also Published As

Publication number Publication date
WO2006044509A2 (en) 2006-04-27
JP2008516962A (en) 2008-05-22
AR051587A1 (en) 2007-01-24
EP1804801A2 (en) 2007-07-11
AU2005295734A1 (en) 2006-04-27
CA2584248A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
WO2006044509A3 (en) Methods of treating vascular injuries
EA200702358A1 (en) COMBINATION OF PDE4 INHIBITOR AND DERIVATIVE TETRAHYDROBIOPTERIN
WO2006009726A3 (en) Substituted urea derivatives for treating cardiac diseases
UY28958A1 (en) NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA
WO2004060318A3 (en) Drug-coated stents and methods of use therefor
NO20054369L (en) Use of an IBAT inhibitor for the treatment and prophylaxis of constipation
DE10294792D2 (en) Coating stents to prevent restenosis
DK1487541T3 (en) Use of IL-18 Inhibitors for the Treatment and / or Prevention of Peripheral Vascular Diseases
ATE448206T1 (en) BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BONE DISEASES
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
ES2414872T8 (en) Combined therapy for the prevention or treatment of Alzheimer's disease and corresponding kit
WO2008005535A3 (en) Expandable vascular endoluminal prostheses
NO20073628L (en) Pyridones useful as inhibitors of kinases
NO20055941L (en) Use of a composition comprising a PDE4 inhibitor and a PDE5 inhibitor
NO20034590D0 (en) Procedures for the treatment of vascular disease
WO2007053610A3 (en) Methods of treating atrial fibrillation wtih pirfenidone
WO2003011274A3 (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma
NO20070651L (en) Compositions of statins with bronchodilators
WO2005000402A3 (en) Anti-adhesion composites and methods os use thereof
WO2009017863A3 (en) Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
NO20043370L (en) N-pyrazinylphenylsulfonamides and their use in the treatment of chemokine-mediated diseases
NO20056218L (en) Substituted pyrrole derivatives and their use as HMF-CoA reductase inhibitors
HK1099918A1 (en) Composition and use for prevention or treatment of stomatitis
ITMI20040876A1 (en) DEHACETYLASE-HDAC HISTONE INHIBITORS-WHICH HYPOLIPIDEMIZED AGENTS FOR THE THERAPY AND PREVENTION OF ARTERIOSCLEROSIS AND CARDIOVASCULAR DISEASES
JP2005511619A5 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005295734

Country of ref document: AU

Ref document number: 554489

Country of ref document: NZ

Ref document number: 2007536868

Country of ref document: JP

Ref document number: 2584248

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005813747

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005813747

Country of ref document: EP